About US
Contact us
-
J&J, Teva offer a whopping $48B combined to wrap opioid suits, but not all plaintiffs are on boardInstead of facing the courtroom in an Ohio bellwether opioid trial, Johnson & Johnson and Teva opted to settle instead. But those deals are just two pieces of a much bigger one in the works: The2019/10/23
-
J&J's Stelara clinches ulcerative colitis nod to back up declining RemicadeUnder assault from newer therapies in the anti-inflammatory market, Johnson & Johnson has focused on expanding Stelara beyond dermatology—and Monday, it took another big step in that direction. T2019/10/22
-
AstraZeneca's Farxiga nabs first CV approval from the FDA. Will a bigger one follow?The Holy Grail for AstraZeneca’s SGLT2 med Farxiga is an approval to treat heart failure in patients with or without diabetes—and it’s well on its way to that goal. But while it waits for that game-c2019/10/22
-
FiercePharmaPolitics—Democrats to name pricing bill in Elijah Cummings' honorWelcome to theFiercePharmapolitical roundup, where each Monday we’ll highlight developments in Washington, D.C., and elsewherethat could affect howdrugmakersoperate. Aspricing debates rage on, the U.2019/10/21
-
Roche's Tecentriq scores a first-in-class double win in new liver cancer patientsRoche is out with phase 3 Tecentriq results in liver cancer, and it’s out in full force. The immuno-oncology med, in combination with fellow Roche drug Avastin, not only showed it could beat Bayer's2019/10/21
-
Gilead's ready to spend big on Descovy, filgotinib launches as hep C and Yescarta struggle: CEOIf Gilead’s investors are worried the company’s new leadership team won’t pony up to support key launches—starting with HIV drug Descovy in PrEP—they don’t need to be, according to CEO Daniel O’Day.2019/10/18
-
Has AstraZeneca finally arrived? Seems so, with oncology and China growth—at least for nowOnce again, AstraZeneca’s newer cancer drugs Tagrisso, Lynparza and Imfinzi, as well as China, have teamed up for growth. But each faces its own fight just around the corner. EGFR lung cancer drug Ta2019/10/18
-
Vertex opens up $500M in sales with landmark CF deal in EnglandA years-long cystic fibrosis drug pricingstandoff has finally yielded a deal, and now thousands of patients in the U.K. are set to access key medicines from Vertex Pharmaceuticals. Vertex and NHS Eng2019/10/17
-
J&J’s third-quarter profits take $3B hit with massive opioid settlementJust three days after pledging to kick in $4 billion of a whopping $48 billion opioid settlement reached with Ohio, Johnson & Johnson is spelling out the impact of the agreement on its bottom lin2019/10/17
-
Lilly counts on growing markets to boost lagging Taltz, TrulicityEli Lilly is counting on Type 2 diabetes drug Trulicity and immunology launchTaltzto keep rollingamid challenges elsewhere. But bothmedsmissed Wall Street'sexpectations, prompting questions from anal2019/10/16